WT1 monitoring in core binding factor AML: Comparison with specific chimeric products

Leukemia Research

Volumn 33, Issue 12, 2009, Pages 1643-1649

  Lasa, Adriana ^a   Carricondo, Maite ^a   Estivill, Camino ^a   Bussaglia, Elena ^a   Gich, Ignasi ^a   Brunet, Salut ^a   Aventin, Anna ^a   Sierra, Jorge ^a   Nomdedéu, Josep F ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

AML1 ETO; CBFB MYH11; Leukemia; Minimal residual disease; WT1

Indexed keywords

CELL PROTEIN; CORE BINDING FACTOR; MYOSIN HEAVY CHAIN; MYOSIN HEAVY CHAIN 11; PROTEIN ETO; RNA; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CD34 SELECTION; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; GENES, WILMS TUMOR; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; MUTATION; RECOMBINANT FUSION PROTEINS; RNA; YOUNG ADULT;

EID: 70249105374     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.03.046     Document Type: Article

References (32)

1. Gabert J., Beillard E., van der Velden V.H., Bi W., Grimwade D., Pallisgaard N., et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukaemia-a Europe Against Cancer program. Leukemia 17 (2003) 2318-2357
2. Call K.M., Glaser T., Ito C.Y., Buckler A.J., Pelletier J., Haber D.A., et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60 (1990) 509-520
3. Hohenstein P., and Hastie N.D. The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet 15 (2006) 196-201
4. Keilholz U., Menssen H.D., Gaiger A., Menke A., Oji Y., Oka Y., et al. Wilms' tumour gene 1 (WT1) in human neoplasia. Leukemia 19 (2005) 1318-1323
5. Yang L., Han Y., Saurez Saiz F., and Minden M.D. A tumor suppressor and oncogene: the WT1 story. Leukemia 21 (2007) 868-876
6. Cilloni D., Gottardi E., De Micheli D., Serra A., Volpe G., Messa F., et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia 16 (2002) 2115-2121
7. Inoue K., Sugiyama H., Ogawa H., Nakagawa M., Yamagami T., Miwa H., et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84 (1994) 3071-3079
8. Barragan E., Cervera J., Bolufer P., Ballester S., Martin G., Fernandez P., et al. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia. Haematologica 89 (2004) 926-933
9. Garg M., Moore H., Tobal K., and Liu Yin J.A. Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. Br J Haematol 123 (2003) 49-59
10. Ogawa H., Tamaki H., Ikegame K., Soma T., Kawakami M., Tsuboi A., et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 101 (2003) 1698-1704
11. Ostergaard M., Olesen L.H., Hasle H., Kjeldsen E., and Hokland P. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients-results from a single-centre study. Br J Haematol 125 (2004) 590-600
12. Weisser M., Kern W., Rauhut S., Schoch C., Hiddemann W., Haferlach T., et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 19 (2005) 1416-1423
13. Lapillonne H., Renneville A., Auvrignon A., Flamant C., Blaise A., Perot C., et al. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol 24 (2006) 1507-1515
14. Cilloni D., Renneville A., Hermitte F., Hills R.K., Daly S., Jovanovic J., et al. Real-time quantitative PCR (RQ-PCR) detection of minimal residual disease (MRD) by optimized WT1 assay to enhance risk stratification in acute myeloid leukemia (AML): a European Leukemia Net study. Blood 110 (2007) [Abs 542]
15. Perea G., Lasa A., Aventin A., Domingo A., Villamor N., Queipo de llano M.P., et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics t(8;21) and inv(16). Leukemia 20 (2006) 87-94
16. Burel S.A., Harakawa N., Zhou L., Pabst T., Tenen D.G., and Zhang D.E. Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol Cell Biol 21 (2001) 5577-5590
17. Cilloni D., Gottardi E., Messa F., Fava M., Scaravaglio P., Bertini M., et al. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes. J Clin Oncol 21 (2003) 1988-1995
18. King-Underwood L., and Pritchard-Jones K. Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood 91 (1998) 2961-2968
19. Virappane P., Gale R., Hills R., Kakkas I., Summers K., Stevens J., et al. Mutation of the Wilms' Tumor 1 Gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 26 (2008) 5429-5435
20. Nyvold C.G., Stentoft J., Braendstrup K., Melsvik D., Moestrup S.K., Juhl-Christensen C., et al. Wilms' tumor 1 mutation accumulated during therapy in acute myeloid leukemia: biological and clinical implications. Leukemia 20 (2006) 2051-2054
21. Summers K., Stevens J., Kakkas I., Smith M., Smith L.L., Macdougall F., et al. Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia 21 (2007) 550-551
22. Valk P.J.M., Verhaak R.G.W., Beijen M.A., Erpelinck C.A.J., van Doorn-Khosrovani S.B.V.W., Boer J.M., et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350 (2004) 1617-1628
23. Hosen N., Sonoda Y., Oji Y., Kimura T., Minamiguchi H., Tamaki H., et al. Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms' tumour gene WT1 at levels similar to those in leukaemia cells. Br J Haematol 116 (2002) 409-420
24. Bruening W., Gros P., Sato T., Stanimir J., Nakamura Y., Housman D., et al. Analysis of the 11p13 Wilms' tumor suppressor gene (WT1) in ovarian tumors. Cancer Invest 11 (1993) 393-399
25. Oji Y., Yano M., Nakano Y., Abeno S., Nakatsuka S., Ikeba A., et al. Overexpression of the Wilms' tumor gene WT1 in esophageal cancer. Anticancer Res 24 (2004) 3103-3108
26. Oji Y., Yamamoto H., Nomura M., Nakano Y., Ikeba A., Nakatsuka S., et al. Overexpression of the Wilms' tumor gene WT1 in colorectal adenocarcinoma. Cancer Sci 94 (2003) 712-717
27. Inoue K., Ogawa H., Sonoda Y., Kimura T., Sakabe H., Oka Y., et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 89 (1997) 1405-1412
28. Boublikova L., Kalinova M., Ryan J., Quinn F., O'Marcaigh A., Smith O., et al. Wilms' tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia 20 (2006) 254-263
29. Loeb D.M., Korz D., Katsnelson M., Burwell E.A., Friedman A.D., and Sukumar S. Cyclin E is a target of WT1 transcriptional repression. J Biol Chem 277 (2002) 19627-19632
30. Nishida S., Hosen N., Shirakata T., Kanato K., Yanagihara M., Nakatsuka S., et al. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. Blood 107 (2006) 3303-3312
31. Ommen H.B., Nyvold C.G., Braendstrup K., Andersen B.L., Ommen I.B., Hasle H., et al. Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Br J Haematol 141 (2008) 782-791
32. Cilloni D., Gottardi E., Fava M., Messa F., Carturan S., Busca A., et al. Usefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detection. Blood 102 (2003) 773-774